Inspire Pharmaceuticals Earnings Conference Call (Q1 2008)  Today's Calls

Visit the TF Network Sites· Corporate IR Center · Institutional Investor Center · Individual Investor Center Download Plug-In Real Player 8 Basic Windows Media Player Other Conference Calls Other May 8 Calls Today's Calls

Call Details Inspire Pharmaceuticals Earnings Conference Call (Q1 2008) Thu, May 8, 2008, 10:00 am Eastern Listen to the archived event audio About Inspire Pharmaceuticals (NasdaqGM:ISPH) Inspire Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing prescription pharmaceutical products for diseases in the ophthalmic and respiratory/allergy areas. The company offers AzaSite, an azithromycin ophthalmic solution and topical anti-infective; Elestat, an epinastine HCl ophthalmic solution and topical antihistamine for the prevention of ocular itching associated with allergic conjunctivitis; and Restasis, a cyclosporine ophthalmic emulsion for the treatment of dry eye disease in adults and children in the United States. Its product candidates in clinical development include Prolacria, a diquafosol tetrasodium for the treatment of dry eye disease in phase 3; Denufosol tetrasodium, an inhaled product for the treatment of cystic fibrosis in phase 3; Epinastine nasal spray for allergic rhinitis in phase 3; and INS115644 for glaucoma in phase 1. It has an agreement with Allergan, Inc. to co-promote Elestat in the U.S., as well as to conduct Phase 4 clinical trials and other studies relating to Elestat in collaboration; and a joint license agreement to develop and commercialize Prolacria, as well as to co-promote Restasis. The company also has a development and license agreement with Boehringer Ingelheim International GmbH to develop and market an intranasal dosage form of epinastine for the treatment or prevention of rhinitis in the U.S. and Canada; a license agreement with InSite Vision Incorporated to commercialize AzaSite, as well as other topical anti-infective products containing azithromycin used in the treatment of human ocular or ophthalmic indications primarily in the U.S. and Canada; and a development, license, and supply agreement with Santen Pharmaceutical Co., Ltd. for the development of diquafosol tetrasodium for the therapeutic treatment of ocular surface diseases in Asia. The company was founded in 1993 and is based in Durham, North Carolina. More Info: Quote | Chart | News | Profile | Reports | Research | SEC | Msgs | Insider | Financials | Analyst Ratings